Regeneron Pharmaceuticals Inc annual earnings per share (EPS) for fiscal TTM was $41.04, a decrease of 1.1% from $41.48 in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| EPS (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (EPS) | $41.04 | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 | $5.52 | $3.07 | $3.81 | $6.50 | $-2.45 | $-1.26 | $-0.85 | $-1.05 | $-1.59 | $-1.77 |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EPS (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (EPS) | $6.75 | $7.86 | $13.62 | $12.81 | $7.27 | $8.06 | $11.54 | $12.41 |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More REGN metrics: Revenue · Gross Profit · Operating Income · Net Income · EBITDA · Free Cash Flow · Shares Outstanding
All REGN financial statements → Interactive REGN charts →
About TickerBase · Data methodology & sources